MindMed Study

*A Phase 2, Multi-center, Randomized, Double-Blind, Parallel-Group, Dose-Finding Study to Assess the Effect of Four Doses of MM-120 for the Treatment of Anxiety Symptoms*

Purpose: To determine the dose-response signal and assess the dose-response relationship of 4 doses of MM-120 (25, 50, 100 or 200 μg free base equivalent)as measured by the change in HAM-A Total Score from Baseline to Week 4

To determine whether MM-120 (25, 50, 100 or 200 μg freebase equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in the following:

• Depressive symptoms
• Anxiety symptoms
• Functional disability
• Quality of life
• Sleep
• Sexual function

Contact: 713-486-2623